10th Nov 2026 10:43
(Alliance News) - The following are the leading risers and fallers among London Main Market small-cap and AIM stocks on Tuesday.
----------
MAIN MARKET SMALL-CAP WINNERS
----------
Pristine Capital PLC, up 33% at 15.00 pence
----------
Chesterfield Resources PLC, up 14% at 0.70p
----------
Nostrum Oil & Gas PLC, up 10% at 0.55p
----------
Nanoco Group PLC, up 9.8% at 2.63p
----------
Gem Diamonds Ltd, up 8.0% at 10.47p
----------
MAIN MARKET SMALL-CAP LOSERS
----------
Hydrogen Utopia International PLC, down 24% at 1.62p
----------
Pensana PLC, down 14% at 45.42p
----------
LMS Capital PLC, down 8.0% at 12.70p
----------
NARF Industries PLC, down 7.5% at 0.18p
----------
Genflow Biosciences PLC, down 6.3% at 1.62p
----------
AIM WINNERS
----------
GCM Resources PLC, up 22% at 11.62 pence
----------
Synergia Energy Ltd, up 17% at 0.007p
----------
Mothercare PLC, up 15% at 0.23p
----------
Mercantile Ports & Logistics Ltd, up 14% at 3.60p
----------
EDX Medical Group PLC, up 13% at 8.75p, launches Caris MI Clarity breast cancer recurrence risk test in the UK
----------
AIM LOSERS
----------
Zanaga Iron Ore Co Ltd, down 23% at 2.30p, says Red Arc Materials transaction unlikely to conclude by November 30
----------
Litigation Capital Management Ltd, down 23% at 0.44p
----------
Quadrise PLC, down 14% at 1.89p
----------
Tern PLC, down 12% at 0.80p
----------
Forgent PLC, down 10% at 0.009p
----------
Small-cap and AIM movers in focus:
----------
EDX Medical Group PLC, up 13% at 8.75 pence, 12-month range 2.30p-9.42p. The Cambridge-based diagnostics company launches what it describes as the first breast cancer prognostic test in the UK capable of assessing both short and long-term risks of recurrence, extending up to 15 years. EDX Medical enters into an agreement with US-based Caris Life Sciences to supply its Caris MI Clarity test in the UK. The artificial intelligence-powered test is designed for postmenopausal patients with HR-positive/HER2-negative, node-negative early-stage breast cancer and assesses recurrence risk at the time of initial diagnosis. It combines tumour pathology images with clinical and molecular data to classify patients as being at low or high risk of recurrence over both the first five years and the subsequent five to 15 years. EDX Medical says the test has been validated using clinical data from tens of thousands of trial participants. Founder and Chief Scientific Officer Chris Evans says: "This test is a very significant step forward in terms of risk assessment and treatment planning for those patients."
----------
Zanaga Iron Ore Co Ltd, down 23% at 2.30 pence, 12-month range 6.50p-13.25p. The iron ore developer says its proposed strategic equity investment by Red Arc Minerals LLC in the Zanaga Iron Ore Project is unlikely to be completed by November 30, as several matters remain unresolved between the parties. Negotiations are continuing in good faith, although Red Arc's exclusivity expired on July 31, allowing Zanaga to explore alternative financing options. The company plans to appoint a financial adviser to conduct a strategic review of all available options, including the proposed Red Arc transaction, and recommend proposals to maximise stakeholder value. Zanaga says Red Arc has provided evidence of significant progress towards securing strategic financing of up to USD500 million. Meanwhile, technical development of the project continues following the completion of a bulk sampling programme, with metallurgical testing and engineering work planned. Non-Executive Chair Clifford Elphick says the company remains committed to discussions with Red Arc but believes it is prudent to broaden its financing options to secure the right funding solution for the project.
----------
Cambridge Nutritional Sciences PLC, down 9.7% at 1.40 pence, 12-month range 1.40p-2.30p. The diagnostics company reports a widening first-half pretax loss to GBP800,000 from GBP400,000 a year earlier, as revenue falls to GBP2.4 million from GBP3.9 million. Cambridge Nutritional Sciences expects full-year sales to be lower than the previous year due to ongoing headwinds, although it says its sales pipeline continues to grow.
----------
Cadence Minerals PLC, up 5.8% at 4.60 pence, 12-month range 3.15p-8.00p. The mineral resources investor says DEV Mineracao SA has secured a five-year operating licence for the Azteca processing plant at the Amapa iron ore project in Brazil, allowing production to begin at a reduced rate. The licence satisfies the remaining condition for the release of a USD1.15 million working capital tranche under an existing prepayment offtake facility, with full-rate operations expected approximately two weeks after the funds are received. Initial production remains constrained by access to feed material, heavy equipment and personnel, with contracts for machinery and staff expected to be finalised in the coming days. The project retains its production target of around 380,000 tonnes annually of iron ore concentrate grading approximately 65% iron. DEV continues to target its first shipment before the end of 2026, subject to funding, plant performance and logistics. Chief Executive Kiran Morzaria says: "The operating licence allows us to run it and sell what it produces."
----------
By Eva Castanedo, Alliance News senior economics reporter
Comments and questions to [email protected]
Copyright 2026 Alliance News Ltd. All Rights Reserved.
Related Shares:
Cambr Nutri SciCadence MineralPristine CapitalChesterfield Resources PLCNostrum Oil&gasNanocoGem Diamonds DiHydrogen UtopiaPensanaLms CapitalNARFGenflow BiosciGCM ResourcesSynergia EnergyMothercareMercantile Ports & LogisticsEdx Medical GrpZanaga Iron Ore Company LimitedLitigation Cap.TernQuadriseForgent